Rein Therapeutics Inc.
RNTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $41 | $10 | $10 | $9 |
| - Cash | $12,865 | $17,313 | $5,194 | $3,600 |
| + Debt | $0 | $48 | $33 | $162 |
| Enterprise Value | -$12,824 | -$17,255 | -$5,151 | -$3,429 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$28,049 | -$15 | -$27 | -$26 |
| % Margin | – | – | – | – |
| Net Income | -$62,883 | -$16 | -$27 | -$26 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.51 | -3.42 | -6.02 | -5.89 |
| % Growth | -2.6% | 43.2% | -2.2% | – |
| Operating Cash Flow | -$22,291 | -$19,808 | -$24,865 | -$23,754 |
| Capital Expenditures | $0 | $0 | $0 | -$157 |
| Free Cash Flow | -$22,291 | -$19,808 | -$24,865 | -$23,911 |